 Treatment immune deficiency syndrome-related Kaposi sarcoma bleomycin single agent nonrandomized trial efficiency toxicity bleomycin single agent treatment non-life-threatening AIDS-related Kaposi sarcoma KS Sixty patients study progressive non-life-threatening AIDS-related KS systemic symptoms lymphocyte count Thirty patients intramuscular bleomycin mg/d days weeks others slow continuous intravenous infusion bleomycin days weeks mean duration therapy months range months partial response patients disease additional patients Bleomycin patients Therapy patients side effects single agent good alternative therapy AIDS-related KS